Gemtuzumab Ozogamicin (Mylotarg) for the Treatment of Acute Myeloid Leukemia – Ongoing Trials

Publisher： Karger

E-ISSN： 2296-5262|30|12|657-662

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.30, Iss.12, 2007-11, pp. : 657-662

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gemtuzumab Ozogamicin (Mylotarg®) in Children with Refractory or Relapsed Acute Myeloid Leukemia

By  

Oncology Research and Treatment, Vol. 27, Iss. 3, 2004-07 ,pp. : 269-272

Karger

Access to resources Recommend Favorite

Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia

By  

CANCER, Vol. 119, Iss. 22, 2013-11 ,pp. : 4036-4043

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pilot Study of Gemtuzumab Ozogamicin (GO), Fludarabine, Cytarabine and Idarubicin Combined Regimen (GO-FLAI) as First-Line Induction Therapy plus GO Alone as Consolidation Therapy for Elderly Acute Myeloid Leukemia Patients

By  

Acta Haematologica, Vol. 118, Iss. 1, 2007-03 ,pp. : 7-9

Karger

Access to resources Recommend Favorite

Post‐transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high‐risk acute myeloid leukaemia

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 5, 2015-06 ,pp. : 756-759

John Wiley & Sons Inc

Access to resources Recommend Favorite

Combination of All-Trans-Retinoic Acid and Gemtuzumab Ozogamicin in an Elderly Patient with Acute Promyelocytic Leukemia and Severe Cardiac Failure

By  

Acta Haematologica, Vol. 117, Iss. 3, 2006-12 ,pp. : 188-190

Karger

Access to resources Recommend Favorite